hackint0sh/New-Dataset huggingface dataset:
Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate. conditions: Bile Duct Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Gemcitabin, Cisplatin and Durvalumab name: Biliary Radiofrequency Ablation name: Endoscopic Retrograde Cholangio-Pancreatography with stenting measure: Any grade 3 or 4 adverse events (AE) leading to chemo-immune checkpoint inhibitor-therapy (CICI) discontinuation up to six months after enrolment. measure: Endoscopic complications as measured by the Adverse events GastRointestEstinal Endoscopy (AGREE) criteria specifically developed for endoscopic interventions measure: Progression-free survival, which is defined as the time till the progression of disease or death, whatever comes first, from the time of enrolment to the end of follow-up. measure: Death from any cause from the time of enrolment to the end of follow-up (overall survival). measure: Development of disease-specific quality-of-life as measured by the EORTC QLQ-BIL21 before every CICI cycle plus at 3 and 6 months from the start of the CICI treatment measure: Change in health-related quality-of-life at baseline, 3 and 6 months from the start of the CICI treatment as measured by the EORTC QLQ-C30 measure: Stent patency at month 3 visit and end of study visit measure: Number of courses of CICI applied measure: Total dose of CICI applied measure: Details of adverse events measure: Prognostic significance of response to intraductal biliary RFA by genetic tumor characterization using next-generation sequencing measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Inselspital Bern University Hospital city: Bern state: Be zip: 3010 country: Switzerland name: Reiner Prof. Dr. med. Wiest role: CONTACT phone: +41 31 632 59 41 email: reiner.wiest@insel.ch name: Martin Prof. Dr. med. Berger role: CONTACT phone: +41 31 632 41 14 email: martin.berger@insel.ch name: Reiner Prof. Dr. med. Wiest role: PRINCIPAL_INVESTIGATOR name: Martin Prof. Dr. med. Berger role: SUB_INVESTIGATOR lat: 46.94809 lon: 7.44744 hasResults: False
nctId: NCT06274866 id: dsahinoglu briefTitle: Effects Of A Home Based Exercise Program Following Total Hip Arthroplasty overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-10 date: 2023-04-30 date: 2024-06-30 date: 2024-02-23 date: 2024-02-23 name: Halic University class: OTHER briefSummary: The aim of this study is to examine the effects of home-based exercise on pain-related factors, postural control and early functional parameters in individuals undergoing total hip arthroplasty. Forty-four individuals with hip osteoarthritis were included in current study. Individuals were randomized as study group (n=23) and control group (n=21) by drawing lots. Individuals in the study group were followed up with a personalized home-based exercise program for 6 weeks. Individuals in the control group were followed up with an exercise training brochure. The exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program. All individuals were evaluated before the operation, 2 weeks after the operation, and 12 weeks after the operation, and their data were recorded. Range of motion was measured with an inclinometer, muscle strength was measured with a hand dynamometer, joint position sense was measured with a target angle test, pain was measured with a visual pain scale, leg length was measured with a tape measure, and finally, the Q angle was measured with a goniometer. In addition to these,Tampa kinesiophobia scale, Oxford hip score and international physical activity scale were used. Timed up-and-go test was used to evaluate functional performance. Foursquare step test was used to evaluate balance, and finally, tetrax posturography device was used to evaluate postural control. conditions: PHYSİOTHERAPY studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomize controlled two groups primaryPurpose: TREATMENT masking: NONE maskingDescription: no blinding count: 48 type: ACTUAL name: exercise program name: control group measure: OXFORD HİP SCORE measure: TAMPA SCALE FOR KINESİOPHOBİA measure: İNTERNATİONAL PHYSİCAL ACTİVİTY QUESTİONAİRE (SHORT FORM) measure: JOİNT POSİTİON SENSE ERROR TEST measure: FOUR SQUARE STEP TEST measure: THE TİMED UP and GO TEST measure: Assessment of Hip Muscle Strength measure: Assessment of Hip Joint Range of Motion measure: Assessment of Postural Control measure: MEASURİNG LEG LENGTH DİSCREPANCY measure: Q ANGLE sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yeditepe Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06274853 id: 170327-0001 id: 6830/0003 type: OTHER domain: ICON plc briefTitle: GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-12 date: 2024-12 date: 2024-02-23 date: 2024-02-23 name: National Center for Advancing Translational Sciences (NCATS) class: NIH name: Leidos Biomedical Research, Inc. name: ICON Government and Public Health Solutions, Inc briefSummary: The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of GS-441524 in healthy subjects. The main questions to answer are: 1) What dosage of GS-441524 is required for adequate therapeutic plasma levels? 2) Does fed or fasted state produce variability in plasma levels? 3) How is GS-441524 eliminated from the body.
Participants will receive varying levels of GS-441524 or placebo to evaluate AEs and plasma levels. conditions: COVID-19 studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 70 type: ESTIMATED name: GS-441524 name: Placebo measure: Treatment-emergent adverse events (TEAEs) measure: Blood Pressure in mm/Hg measure: Pulse in beats/min measure: Respiratory Rate in breaths per minute measure: Body Temperature in degrees measure: Electrocardiogram (ECG) as measured by PR interval measure: Electrocardiogram (ECG) as measured by QT interval measure: Electrocardiogram (ECG) as measured by QT corrected (Fridericia's) measure: Plasma PK Parameter C-Max measure: Plasma PK Parameter t-max measure: Plasma PK Parameter t-lag measure: Plasma PK Parameter AUC 0-last measure: Plasma PK Parameter AUC 0-inf measure: Plasma PK Parameter t 1/2 measure: Plasma PK Parameter CL/F measure: Plasma PK Parameter Vz/F measure: Urine PK Parameter Ae urine measure: Urine PK Parameter Fe urine measure: Urine PK Parameter CL R measure: Plasma PK Parameter C trough measure: Plasma PK Parameter AUC 0-tau measure: Plasma PK Parameter CL/F ss measure: Plasma PK Parameter Vz/F ss measure: Plasma PK Parameter R ac sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06274840 id: CAR-CF briefTitle: COVID-19 Antibody Responses In Cystic Fibrosis acronym: CAR-CF overallStatus: RECRUITING date: 2022-08-08 date: 2024-05 date: 2024-05 date: 2024-02-23 date: 2024-02-23 name: Pilar Azevedo class: OTHER name: Queen's University, Belfast name: European Cystic Fibrosis Society - Clinical Trial Network name: Cystic Fibrosis Foundation name: Medical University Innsbruck briefSummary: Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or whether pwCF have protective genetic/immune factors. This study aims to prospectively assess the proportion of pwCF, including both adults and children with CF who have evidence of SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this has on their CF disease. The proposed study will recruit pwCF from paediatric and adult CF centres in Europe. Serological testing to detect antibodies will be performed on blood samples taken at month 0, 6, 12, 18 and 24 with additional time-points if bloodwork is available via normal clinical care. Clinical data on, lung function, CF-related medical history, pulmonary exacerbations, antibiotic use, and microbiology and vaccination receipt, will be collected during routine clinical assessments.
Associations will be examined between socio-demographic and clinical variables and serologic testing. The effects of SARS-CoV-2 infection on clinical outcomes and analyse end-points will be examined to explore any age-related or gender-based differences, as well as subgroup analysis of outcomes in lung-transplant recipients and pwCF receiving CFTR modulator therapies. As pwCF receive COVID-19 vaccination a comparison of the development and progression of anti-SARS-CoV-2 antibodies in pwCF following natural infection and vaccination SARS-CoV-2 over time will be performed. conditions: COVID-19 conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: SARS-COV-2 seroprevalence measure: Association of SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF measure: Longitudinal comparison of the detection measure: Serum proteomic and genomic responses of pwCF sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: CHLN status: RECRUITING city: Lisboa zip: 1800-268 country: Portugal name: Celeste Barreto role: CONTACT name: Ana Lopes role: CONTACT name: Celeste Barreto, MD role: PRINCIPAL_INVESTIGATOR lat: 38.71667 lon: -9.13333 hasResults: False
nctId: NCT06274827 id: GO 22- 881 briefTitle: Electromyographic Analysis of Scapular Muscles During Closed Kinetic Chain Exercises overallStatus: COMPLETED date: 2022-09-25 date: 2023-04-30 date: 2023-06-20 date: 2024-02-23 date: 2024-02-26 name: Hacettepe University class: OTHER briefSummary: In shoulder rehabilitation, the inclusion of kinetic chain exercises is advocated in order to provide the necessary energy transfer to produce optimal force with minimal energy consumption. Closed kinetic chain (CKC) exercises are defined as exercises in which the distal segment is stabilized by encountering significant resistance while the proximal segment moves. In contrast, open kinetic chain (OKC) exercises allow the distal segment to move freely without any resistance. Recently, the importance of closed kinetic chain (CKC) exercises has increased in enhancing shoulder joint neuromuscular control by improving dynamic shoulder stability and joint position sense.
The most current shoulder rehabilitation protocols include exercises for restoration of scapular muscle imbalances.There exist studies investigating the levels of scapular muscle activation during CKC exercises. Researchers have shown that most CKC exercises especially push-ups and plank variations with the shoulder in the 90° position, generally provide high SA activity and an optimal UT/SA ratio.In the literature, there is limited information on how the level of shoulder elevation affects scapular muscle activity and ratio during closed kinetic chain exercises in the prone position. To effectively prescribe CKC exercises commonly used in rehabilitation and athletic programs, a clear understanding of shoulder elevation changes muscle activity during these exercises is required.
Our hypothesis is that glenohumeral joint elevation status will alter scapular muscle activation and activation rates. conditions: Shoulder Pain conditions: Shoulder Injuries conditions: Activation, Patient studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All participants will complete each stage in a randomized order. primaryPurpose: BASIC_SCIENCE masking: NONE count: 22 type: ACTUAL name: Superficial Electromyography measure: Muscle activation recorded with surface electromyography (sEMG) during CKC sex: MALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Hacettepe University city: Ankara zip: 06430 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06274814 id: AP23.501.038 briefTitle: U/S Guided Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block vs Type 2 Pectoral Nerve Block overallStatus: RECRUITING date: 2023-06-01 date: 2024-04-01 date: 2024-05-01 date: 2024-02-23 date: 2024-03-13 name: National Cancer Institute, Egypt class: OTHER briefSummary: The aim of this study is to compare between U/S Guided Rhomboid Intercostal Block Combined with Sub-Serratus Plane Block vs type 2 Pectoral Nerve Block in Analgesia for Breast Cancer Surgery by measuring intraoperative hemodynamics, postoperative pain scores and morphine consumption in the first 24 h postoperative. conditions: Breast Neoplasm Female conditions: Analgesics studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 69 type: ESTIMATED name: U/S guided Rhomboid intercostal block (RIB) name: U/S guided RIB combined with the sub-serratus plane block (RISS) measure: Total morphine consumption measure: Visual Analog scale score postoperative measure: Intraoperative fentanyl consumption measure: Heart rate intraoperative measure: Timing of first rescue analgesia sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National cancer Insititute status: RECRUITING city: Cairo zip: 11796 country: Egypt name: attef, lecturer role: CONTACT phone: +20225328286 email: irb@nci.cu.edu.eg name: ahmed soliman role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06274801 id: GB002-3102 id: 2023-506334-75 type: EUDRACT_NUMBER briefTitle: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-12 date: 2026-12 date: 2024-02-23 date: 2024-02-23 name: GB002, Inc. class: INDUSTRY briefSummary: This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study conditions: Pulmonary Arterial Hypertension studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: Seralutinib name: Gereic Dry Powder Inhaler measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Changes in distance achieved on the Six-Minute Walk Test (6MWT) measure: Changes in NT-proBNP sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kansas Medical Center city: Kansas City state: Kansas zip: 66160 country: United States lat: 39.11417 lon: -94.62746 facility: Pulmonary Associates of Richmond, Inc. city: Richmond state: Virginia zip: 23230 country: United States lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06274788 id: OMEG-054-CP4 briefTitle: Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-01 date: 2027-03-01 date: 2024-02-23 date: 2024-03-12 name: Fresenius Kabi class: INDUSTRY briefSummary: This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population conditions: Parenteral Nutrition Associated Liver Disease (PNALD) conditions: Essential Fatty Acid Deficiency conditions: Malnutrition conditions: Pediatric ALL studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: Omegaven® (fish oil triglycerides) Injectable Emulsion measure: Incidence of essential fatty acid deficiency (EFAD) measure: Incidence of clinical EFAD measure: Time from treatment start to EFAD diagnosis measure: Incidence of adverse events (AEs)/serious adverse events (SAEs) measure: Routine laboratory tests: Direct or conjugated bilirubin measure: Routine laboratory tests: triglycerides measure: Fatty acid profiles: α-linolenic acid measure: Fatty acid profiles: linoleic acid measure: Fatty acid profiles: arachidonic acid measure: Fatty acid profiles: mead acid measure: Fatty acid profiles: oleic acid measure: Fatty acid profiles: docosahexaenoic acid (DHA) measure: Fatty acid profiles: eicosapentaenoic acid (EPA) measure: Anthropometric measures: body weight measure: Anthropometric measures: body height/length measure: Anthropometric measures: head circumference sex: ALL minimumAge: 1 Day maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06274775 id: 23-12026811 briefTitle: Effect of an Educational Nail Biopsy Video on Pre-operative Anxiety, Health Literacy, and Patient Satisfaction overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-07 date: 2025-07 date: 2024-02-23 date: 2024-04-12 name: Weill Medical College of Cornell University class: OTHER briefSummary: The investigators are interested in studying the effect of an animated video depicting a nail biopsy procedure on the anxiety, health literacy, and satisfaction of participants recommended to undergo a nail biopsy procedure. The investigators hypothesize that the animated video will reduce preoperative anxiety, increase health literacy, and increase patient satisfaction in relation to nail biopsy procedures. conditions: Anxiety conditions: Literacy conditions: Satisfaction, Patient studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Educational Video measure: Anxiety, as measured by the State Trait Anxiety Inventory measure: Anxiety, as measured by the Amsterdam Preoperative Anxiety and Information Scale measure: Need for information, as measured by the Amsterdam Preoperative Anxiety and Information Scale measure: Health literacy, as measured by 4 domains of The Health Literacy Questionnaire measure: Patient satisfaction, as measured by a patient satisfaction survey measure: Quality of video intervention for intervention participants, as measured by a qualitative feedback survey sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Weill Cornell Medicine city: New York state: New York zip: 10065 country: United States name: Shari R. Lipner, MD, PhD role: CONTACT email: shl9032@med.cornell.edu name: Rachel C Hill, BS role: CONTACT phone: 5024170984 email: shl9032@med.cornell.edu lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06274762 id: MARU-SBF-ROKÇ-01 briefTitle: Visually Impaired Women Model-based Cancer Education and Breast Self-examination overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-31 date: 2025-03-31 date: 2024-02-23 date: 2024-02-23 name: Marmara University class: OTHER briefSummary: The aim of our study was to raise awareness among visually impaired women, who are in the vulnerable group, about breast cancer, which ranks first among female cancers, and to teach breast self-examination. conditions: Breast Cancer Awareness and BSE in Visually Impaired Women studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: There is an experimental group of 45 visually impaired women aged 20-69 and a control group of 45. Randomization was not possible. Blinding could not be done. primaryPurpose: PREVENTION masking: NONE count: 90 type: ESTIMATED name: Training and BSE application on a model measure: Champion health belief model scale sex: FEMALE minimumAge: 20 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University city: Istanbul country: Turkey name: Marmara University role: CONTACT email: sevalsaray.demir@gmail.com name: Seval Saraydemir Kıromeroglu role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06274749 id: 10001930 id: 001930-AG briefTitle: Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial overallStatus: RECRUITING date: 2024-05-01 date: 2027-03-31 date: 2027-03-31 date: 2024-02-23 date: 2024-04-26 name: National Institute on Aging (NIA) class: NIH briefSummary: Background:
Imaging scans of the thigh; scans of the brain are optional.... conditions: Healthy Volunteer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: Urolithin A name: Placebo measure: To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation. measure: To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation. measure: To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation. measure: To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation. measure: To determine if UA supplementation will alter gut microbiome composition. sex: ALL minimumAge: 55 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of Aging, Clinical Research Unit status: RECRUITING city: Baltimore state: Maryland zip: 21224 country: United States name: Josephine Egan, M.D. role: CONTACT phone: 410-558-8414 email: eganj@mail.nih.gov lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06274736 id: CLINP-001012 briefTitle: Safety and Performance of Motiva® Sizers overallStatus: RECRUITING date: 2023-04-10 date: 2027-04-10 date: 2027-07-10 date: 2024-02-23 date: 2024-02-23 name: Establishment Labs class: INDUSTRY briefSummary: The Motiva® Sizer clinical study is a four-year, multicenter, post-marketing, and cohort study, designed to confirm the safety and performance of Motiva® Sizer in breast augmentation or reconstruction procedures.
The research will include 330 women, divided into two groups of 165 participants each (150 breast augmentation participants and 15 reconstruction participants). The Motiva® Sizer exposed group will consist of women who will undergo breast augmentation or reconstruction surgery with the use of Motiva® Sizer during the procedure, and a non-exposed group will consist of women who will undergo breast augmentation or reconstruction surgery without the use of Motiva® Sizer. This study will be conducted in Costa Rica.